ACRES Commercial RealtyNYSE: ACR

– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –

ACRES Commercial Realty is trading for 66 cents on the dollar. The mREIT continues to buy back shares and has $4.1 million outstanding on its buyback program. CECL reserve and the CRE loan portfolio risk rating were both up sequentially.

Acrivon Therapeutics shows promise in precision oncology with its AP3 platform and positive Phase 2 data for ACR-368, indicating potential for significant stock growth. Acrivon's robust pipeline, including the accelerated development of ACR-2316, and a strong cash position, highlight its commitment to advancing innovative cancer therapies. Despite being pre-revenue and operating at a loss due to high R&D expenses, ACRV maintains a healthy cash balance, crucial for ongoing operations and development.

UNIONDALE, N.Y. , Sept. 17, 2024 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

WATERTOWN, Mass., Sept. 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platform for the discovery, design, and development of drug candidates through a mechanistic match to patients whose disease is predicted sensitive to the specific treatment, today presented additional positive clinical data at ESMO from the ongoing registrational intent, multicenter Phase 2 trial of ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. The company has also disclosed that the Investigational New Drug (IND) application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024.

ACRES Commercial Realty Corp. (NYSE:ACR ) Q2 2024 Earnings Call Transcript August 1, 2024 10:00 AM ET Company Participants Kyle Brengel - VP of Operations Mark Fogel - President and CEO Eldron Blackwell - CFO Andrew Fentress - Chairman Conference Call Participants Stephen Laws - Raymond James Chris Muller - Citizens JMP Operator Good day, ladies and gentlemen, and welcome to the Second Quarter 2024 ACRES Commercial Realty Corp. Earnings Conference Call. Currently, all participants are in a listen-only mode.

ACRES Commercial (ACR) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.60 per share a year ago.

Investors need to pay close attention to ACRES Commercial (ACR) stock based on the movements in the options market lately.

ASGN, AMWD and ACR have been added to the Zacks Rank #5 (Strong Sell) List on June 5, 2024.